EVRENZO’s advantages of being first-to-market and possessing a broader label are likely to be key factors influencing VAFSEO uptake, according
US dermatologists’ perceptions and experience with Sotyktu likely impacting their take on the entire TYK2 class for the treatment of
Spherix Global Insights find JAK inhibitors, led by AbbVie’s Rinvoq, establishing significant footholds in both first and later line UC
Bariticinib (Olumiant; Eli Lilly) is prescribed by the majority of US dermatologists to their patients with alopecia areata (AA), according
Despite little prescriber differentiation between the JAKs, including satisfaction and manufacturer perceptions, Olumiant is projected to maintain a significant market
Fewer than half of those dealing with Parkinson’s disease in the United States are able to gain clinical control of
Prior to launch, prescribers estimate that TNF inhibitors are likely to bear the greatest brunt of increased adoption of the
PHILADELPHIA — Results of a survey conducted in the U.S. and abroad showed that most nephrologists remain wary about prescribing
Lupus patients desire more targeted information on specific treatments available, underscoring an opportunity for the pharmaceutical industry to play a
Gene therapies and LRRK2 inhibition are at the forefront of prescribers’ interest, highlighting the need for a truly disease modifying
Despite Vabysmo’s gains in 2023, Eylea HD will prove to be a formidable force in the coming year. [Exton PA,
According to Spherix Global Insights, US nephrologists have expressed a high level of enthusiasm for Novartis’ iptacopan and atrasentan, as
